Results 111 to 120 of about 2,546 (158)

Highly sensitive and rapid determination of Coxsackievirus A16 using restriction endonuclease-mediated reverse transcription multiple cross displacement amplification. [PDF]

BMC Microbiol
Liang Q, Cao Y, Zhang X, Ye R, Liu M, Zhang S, Wang Y.   +6 more
europepmc   +1 more source

Genetic and Cross Neutralization Analyses of Coxsackievirus A16 Circulating in Taiwan from 1998 to 2021 Suggest Dominant Genotype B1 can Serve as Vaccine Candidate. [PDF]

Viruses, 2022
Cheng D, Chiu YW, Huang SW, Lien YY, Chang CL, Tsai HP, Wang YF, Wang JR.   +7 more
europepmc   +1 more source

Seroprevalence of coxsackievirus A16 antibody among people of various age groups: a systematic review and meta-analysis. [PDF]

Arch Public Health, 2021
Li P, Chen Y, Tang A, Gao F, Yan JB.
europepmc   +1 more source

The transfer of maternal antibodies and dynamics of maternal and natural infection-induced antibodies against coxsackievirus A16 in Chinese children 0-13 years of age: a longitudinal cohort study. [PDF]

BMC Med, 2022
Zhou J, Zhou Y, Luo K, Liao Q, Zheng W, Gong H, Shi H, Zhao S, Wang K, Qiu Q, Dai B, Ren L, Wang L, Gao L, Xu M, Liu N, Lu W, Zheng N, Chen X, Chen Z, Yang J, Cauchemez S, Yu H.   +22 more
europepmc   +1 more source

Intertypic Recombination Between Coxsackievirus A16 and Enterovirus A71 Structural and Non-Structural Genes Modulates Virulence and Protection Efficacy. [PDF]

Vaccines (Basel)
Chang HY, Tee HK, Ong KC, Jasni K, Abdullah S, Sam IC, Chan YF.   +6 more
europepmc   +1 more source

The near-complete genome of coxsackievirus A16 genotype B1c causing hand, foot, and mouth disease in Thailand, 2023. [PDF]

Microbiol Resour Announc
Taoma K, Sittikul P, Chuaysri J, Sriburin P, Nuprasert W, Rattanamahaphoom J, Kosoltanapiwat N, Leaungwutiwong P, Thaipadungpanit J, Chatchen S.   +9 more
europepmc   +1 more source

Correction: Chang et al. Intertypic Recombination Between Coxsackievirus A16 and Enterovirus A71 Structural and Non-Structural Genes Modulates Virulence and Protection Efficacy. <i>Vaccines</i> 2025, <i>13</i>, 1017. [PDF]

Vaccines (Basel)
Chang HY, Tee HK, Ong KC, Jasni K, Abdullah S, Sam IC, Chan YF.   +6 more
europepmc   +1 more source

Virtual flavonoids screening identifies potent compounds against enterovirus A71 and coxsackievirus A16

, 2023
Sripattarp A, Sanachai K, Chavasiri W, Wolschann P, Langer T, Boonyasuppayakorn S, Rungrotmongkol T.   +6 more
europepmc   +1 more source

A New Human SCARB2 Knock-In Mouse Model for Studying Coxsackievirus A16 and Its Neurotoxicity. [PDF]

Viruses
Wu H, Wang Z, Zhang Y, Hu L, Yang J, Zhang C, Lou M, Pi N, Wang Q, Fan S, Huang Z.   +10 more
europepmc   +1 more source

Optimization of Vero Cells Grown on a Polymer Fiber Carrier in a Disposable Bioreactor for Inactivated Coxsackievirus A16 Vaccine Development. [PDF]

Vaccines (Basel), 2021
Chen K, Li C, Wang Y, Shen Z, Guo Y, Li X, Zhang Y.   +6 more
europepmc   +1 more source